STRATA Skin Sciences faces a challenging transition as it attempts to scale the TheraClear X platform amidst a shrinking asset base and persistent operational losses. While the company maintains a 60.4% gross margin, the inability to achieve operating leverage...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
Medical device veteran poised to lead STRATA to market leadership and continued revenue growth as Company continues next development phase Medical device veteran poised to lead STRATA to market leadership and continued revenue growth as Company continues next development phase
Benchmark SSKN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for STRATA Skin Sciences, Inc. (SSKN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.01 | $29.44K | -0.00 | -8.54% | -20.4% | -158.91% | — | |
| $7.25 | $199.53M | -15.43 | 10.2% | -8.95% | -20.23% | — | |
| $0.67 | $87.25M | -4.21 | -10.02% | -9.79% | -47.84% | — | |
| $100.00 | $6.51B | 29.33 | 0.5% | 17.69% | 23.27% | — | |
| $14.45 | $830.6M | 10.10 | -6.16% | 20.69% | 11.8% | — | |
| $7.29 | $91.08M | -29.16 | 14.52% | -10.92% | -108.8% | — |
STRATA Skin Sciences, Inc. (SSKN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
STRATA Skin Sciences, Inc. (SSKN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Feb 11, 2026·SEC
Dec 17, 2025·SEC
Dec 10, 2025·SEC
Get notified when SSKN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
STRATA Skin Sciences, Inc. (SSKN) stock FAQ — growth, dividends, profitability & financials explained
STRATA Skin Sciences, Inc. (SSKN) reported $30.7M in revenue for fiscal year 2025.
STRATA Skin Sciences, Inc. (SSKN) saw revenue decline by 8.5% over the past year.
STRATA Skin Sciences, Inc. (SSKN) reported a net loss of $6.5M for fiscal year 2025.
STRATA Skin Sciences, Inc. (SSKN) has a return on equity (ROE) of -158.9%. Negative ROE indicates the company is unprofitable.
STRATA Skin Sciences, Inc. (SSKN) had negative free cash flow of $4.3M in fiscal year 2025, likely due to heavy capital investments.
